CMS Energy(US:CMS) Prnewswire·2024-11-01 21:22Core Points - The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral renal denervation (RDN) catheter, effective January 1, 2025, for up to three years [1][2][3] - The TPT program aims to enhance patient access to innovative healthcare technologies by reducing cost barriers for healthcare systems [3] - The Medtronic Symplicity Spyral RDN System, approved by the FDA in November 2023, is a minimally invasive procedure that targets overactive nerves near the kidneys to help lower blood pressure [4][5] Company Overview - Medtronic plc is a leading global healthcare technology company headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across more than 150 countries and offers technologies that treat 70 health conditions, including cardiac devices and surgical tools [6] - The Symplicity Spyral RDN System is part of a comprehensive clinical program studying renal denervation in various patient populations, with over 25,000 patients treated globally [5]